talquetamab + pomalidomide

Talquetamab + pomalidomide is an experimental combination regimen under evaluation for the treatment of relapsed/refractory multiple myeloma. **Talquetamab** is a bispecific monoclonal antibody targeting CD3 (on T-cells) and GPRC5D (on myeloma plasma cells), redirecting T-cell cytotoxicity toward myeloma cells by facilitating the formation of an immune synapse and activation of T-cell-mediated killing. **Pomalidomide** is an immunomodulatory small molecule (IMiD) that inhibits myeloma cell growth and augments T-cell and NK-cell activity. The combination enhances T-cell activation, the release of cytotoxic granules (granzyme B, perforin), and decreases regulatory T-cell frequency, resulting in improved anti-myeloma activity[1][2][4][5]. Clinical trials (MonumenTAL-2, MonumenTAL-3) have shown high overall response rates and manageable toxicity profiles for this combination in patients with heavily pretreated and high-risk myeloma.

Other names

talquetamab plus pomalidomideTal-P